Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Loss of IGSF1 gene function causes central hypothyroidism

Loss of function in the X-linked immunoglobulin superfamily member 1 (IGSF1) gene causes central hypothyroidism, testicular enlargement, and variable prolactin deficiency, according to data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.

21 Sep 2012

Vitamin E may prevent cancer in patients with Cowden Syndrome

Cleveland Clinic researchers have discovered that vitamin E may prevent cancer in patients with an under-recognized genetic disorder.

18 Sep 2012

ATA, AACE develop new guidelines for diagnosis and treatment of hypothyroidism

New evidence-based guidelines have been released for the diagnosis and treatment of hypothyroidism, a complex disease caused by an underactive thyroid gland that cannot produce enough thyroid hormone.

13 Sep 2012

Voice therapy should be offered to more thyroidectomy patients

Voice problems following surgery to remove the thyroid gland are a common problem reported by patients, but only a minority are offered voice therapy, show results from a US study.

5 Sep 2012

New York State Department of Health issues license to Veracyte's Afirma Gene Expression Classifier

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company, today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma Gene Expression Classifier to be offered to patients in the state.

30 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

FDA accepts Exelixis’ cabozantinib NDA for filing

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

30 Jul 2012

Coca-Cola sold in California now contains little of cancer-causing chemical 4-methylimidizole

Carcinogenicity and regulation of caramel colorings by Michael Jacobson, (Executive Director, Center for Science in the Public Interest, USA), an article due to be published in the International Journal of Occupational and Environmental Health, states that Coca-Cola sold in California now contains little of the cancer-causing chemical 4-methylimidizole (4-MI).

27 Jul 2012

Third-party groups to target health law with new wave of attack ads

Also in the news, the Supreme Court -- especially after the recent health law decision -- is an effective tool to rally fundraising among both Democrats and Republicans. Meanwhile, a defense policy expert suggests presidential candidates focus on long-term military mental health issues. Finally, The Wall Street Journal examines how health care is playing in the Montana Senate race, where candidates are sparring over who is soft on cancer.

23 Jul 2012

First Edition: July 23, 2012

In this Kaiser Health News video, Greg Millett, a senior policy advisor in the Office of National AIDS Policy, tells Joanne Silberner that the president's National HIV/AIDS Strategy has improved coordination among federal agencies and that the 2010 health law will improve access to care for those living with HIV/AIDS.

23 Jul 2012

New method uses acoustic angiography to identify cancer in minutes

From the air, the twists and turns of rivers can easily be seen. In the body, however, tracing the twists and turns of blood vessels is difficult, but important. Vessel "bendiness" can indicate the presence and progression of cancer.

11 Jul 2012

Afirma gene expression test can reduce unnecessary thyroid cancer surgeries

Veracyte, Inc., a molecular diagnostics company that is pioneering the emerging field of molecular cytology, today announced results from a large, prospective, multicenter study, which demonstrated the potential for the Afirma® Gene Expression Classifier, a gene expression test, to reduce the large number of unnecessary surgeries in thyroid cancer diagnosis by more than half.

25 Jun 2012

FOXO3a transcription factor actually promotes growth of anaplastic thyroid cancer

A molecule widely believed to fight many forms of cancer actually helps deadly thyroid tumors grow, and cancer therapies now being tested in humans might boost the activity of this newly revealed bad guy, researchers at Mayo Clinic in Florida say.

21 Jun 2012

New approach to drug design may yield more effective and less toxic cancer medicines

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.

16 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

Exelixis commences cabozantinib phase 3 pivotal trial in mCRPC

Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.

31 May 2012

Exelixis files NDA with FDA for cabozantinib to treat MTC

Exelixis, Inc. today announced that it has completed the filing of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer.

30 May 2012